Arthneeti
AksharChem (I)Q1 FY20

AksharChem (I) Q1 FY20 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹382P/E: 27.5Market Cap: ₹340 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 2 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • The textile industry in India is projected to grow at over 10% CAGR over the next 5 years (Page 26).
  • Exports, a key focus area, are expected to grow at a CAGR of approximately 15% over the next 5 years (Page 26).
  • The company plans to widen its product portfolio with value-added products and expand its presence geographically in Southeast Asia, NAFTA, and India to provide a geographic hedge (Page 24).
  • Focus on developing strong business relationships and maintaining an extensive supply chain network worldwide supports growth (Page 24).
  • The company achieved 85% capacity utilization through better planning, indicating potential for higher volumes with further efficiency (Page 23).
  • Expansion plans include increasing capacity in key segments like organic pigments (CPC Green), dyes & intermediates, and specialty chemicals (Page 10).

See what AksharChem (I) management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The document does not explicitly mention any current or planned new fundraising through debt or equity.
  • As of March 2019, the company is a net cash company with zero borrowings (Debt to Equity ratios are very low: 0.0 to 0.4 across FY15-FY19).
  • The company has a strong debt rating (CARE A1+ for short-term and CARE A+/CARE A1+ for long/short term bank facilities), indicating good access to debt markets if needed.
  • The IPO was historically used to fund plant capacity expansion (mentioned on page 13), but no recent or future equity fundraising is stated.
  • Overall, the company focuses on financial prudence and has faced no bad debt till now, suggesting no immediate need for raising funds through debt or equity based on the available data.

See what AksharChem (I) management said on order book — free account, 30 seconds.

Capex plans

Yes
  • CAPEX plan announced for expansion in:
  • - CPC Green capacity: from 1,920 TPA to 2,400 TPA (additional 480 TPA)
  • - H Acid: new capacity of 1,200 TPA
  • - Precipitated Silica: new capacity of 10,000 TPA
  • Recent expansions include addition of 480 TPA of CPC Green and 1,200 TPA of H Acid during H1 FY19.
  • Focus on investments in quality certifications and process automation technologies aiming at superior technology-driven products.
  • Emphasis on modernizing technologies to improve quality, reduce human error, and enhance productivity.
  • Long-term growth strategies include widening the product portfolio with value-added products and extending geographic presence in South East Asia, NAFTA, and India for geographic hedge.

Track AksharChem (I) — get its next earnings analysis in your feed

Margin guidance

- The company projects growth driven by expanding product portfolio with value-added products and geographic expansion in South East Asia, NAFTA, and India (Page 24). - Export-focused industry with exports expected to grow at ~15% CAGR over the next 5 years (Page 26). - Textile industry in India, a key end-user, projected to grow at over 10% CAGR over the next 5 years, supporting demand (Page 26). - Historical strong revenue CAGR of 22% and net worth CAGR of 57% FY13-19 (Page 12). - Expected improvements in operational efficiency through better planning and higher plant uptime (Page 23). - Despite Q1 FY20 revenue and volumes impacted by economic slowdown, consistent gross profit margins (~35-37%) and EBITDA margins (~6.7-11.3%) indicate stable profitability (Pages 4-6). - Long-term outlook considered bright with ongoing investments shaping future success and returns (Page 8). Overall, the company expects sustainable earnings and EPS growth supported by geographic expansion, export growth, and operational improvements.

Order book

The provided pages of the PDF do not contain explicit details on the current or expected order book or pending orders for the company. However, some related insights can be summarized as follows: - The company has long-term quantity contracts with leading global customers, indicating stable order inflows (Page 16, 27). - FY17 was noted as an exceptional year due to a Chinese clampdown, which may have influenced order volumes and demand (Pages 29, 30). - There is a focus on extending presence in South East Asia, NAFTA, and India to provide geographic hedge, suggesting expected growth in orders from these regions (Page 24). - The company achieved 85% capacity utilization in FY19, implying strong order execution and plant uptime (Page 23). - Revenues were impacted recently due to low volumes and softening prices, with demand slowdown from end-user industries (Page 4). No specific numeric data on the current or expected order book or pending orders is provided.

How does AksharChem (I) rank vs peers in Chemicals & Petrochemicals?

Pro feature
ThisAksharChem (I)
Rev 3
See where AksharChem (I) sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does AksharChem (I) rank in Chemicals & Petrochemicals?

Compare AksharChem (I) against every Chemicals & Petrochemicals company (Q1 FY20) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

Continue your research

What AksharChem (I)'s management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Sudarshan Chemical Industries Ltd (Q1 FY27)

    The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…

  • Indo Borax & Ch. (Q1 FY27)

    250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…

  • SRF Ltd (Q1 FY27)

    Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…

  • Deepak Fertilis. (Q1 FY27)

    Long-term demand-supply balance looks stable with 6-7% market growth, supporting sustained revenues despite new capacity additions. Key concall takeaways from…

Compare:vs Solar Industries India Ltdvs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →